Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.

Signal transduction and targeted therapy - 9 Dec 2024

Yi Zongbi, Feng Kaixiang, Lv Dan, Guan Yanfang, Shao Youcheng, Ma Fei, Xu Binghe

Abstract excerpt

The large population of HER2-low breast cancer patients necessitates further research to provide enhanced clinical guidance. In this study, we retrospectively analyzed 1071 metastatic breast cancer (MBC) patients and the circulating tumor DNA (ctDNA) to investigate clinicopathological and genetic alterations of HER2-low MBC patients. The effect of HER2-low status on different treatment modalities was explored in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aminoquinolines
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Class I Phosphatidylinositol 3-Kinases

Share to Clinical Trials as Topic

Share to Neoplasm Metastasis

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 39648226
DOI: 10.1038/s41392-024-02047-0
PMCID: PMC11625825

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.PMID 39648226Read ↗

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.Semantic proximity Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.Semantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

Landscape of circulating tumour DNA in metastatic breast cancer.Semantic proximity Read ↗

Genomic Alterations of Tumors in HER2-Low Breast Cancers.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.